BR0315054A - Ligando induzìvel para a integrina alfa 1 beta 1 e empregos - Google Patents

Ligando induzìvel para a integrina alfa 1 beta 1 e empregos

Info

Publication number
BR0315054A
BR0315054A BR0315054-2A BR0315054A BR0315054A BR 0315054 A BR0315054 A BR 0315054A BR 0315054 A BR0315054 A BR 0315054A BR 0315054 A BR0315054 A BR 0315054A
Authority
BR
Brazil
Prior art keywords
integrin
jobs
beta
alpha
inductively linking
Prior art date
Application number
BR0315054-2A
Other languages
English (en)
Inventor
Dominic Cosgrove
Original Assignee
Boys Town Nat Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boys Town Nat Res Hospital filed Critical Boys Town Nat Res Hospital
Publication of BR0315054A publication Critical patent/BR0315054A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"LIGANDO INDUZìVEL PARA A INTEGRINA ALFA1BETA1 E EMPREGOS". A presente invenção é direcionada à identificação e empregos de agentes, particularmente peptídeos e anticorpos monocionais que rompem a interação entre o Colágeno XIII e a integrina <244>1<225>1.
BR0315054-2A 2002-11-01 2003-10-31 Ligando induzìvel para a integrina alfa 1 beta 1 e empregos BR0315054A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42329702P 2002-11-01 2002-11-01
PCT/US2003/034818 WO2004041846A2 (en) 2002-11-01 2003-10-31 INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES

Publications (1)

Publication Number Publication Date
BR0315054A true BR0315054A (pt) 2005-08-16

Family

ID=32312635

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315054-2A BR0315054A (pt) 2002-11-01 2003-10-31 Ligando induzìvel para a integrina alfa 1 beta 1 e empregos

Country Status (14)

Country Link
US (2) US7348002B2 (pt)
EP (1) EP1562632B1 (pt)
JP (1) JP2006516024A (pt)
KR (1) KR20050084921A (pt)
CN (1) CN1826137A (pt)
AU (1) AU2003287435A1 (pt)
BR (1) BR0315054A (pt)
CA (1) CA2504125A1 (pt)
EA (1) EA200500576A1 (pt)
IS (1) IS7832A (pt)
MX (1) MXPA05004563A (pt)
NO (1) NO20052495L (pt)
PL (1) PL376714A1 (pt)
WO (1) WO2004041846A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0315054A (pt) * 2002-11-01 2005-08-16 Boys Town Nat Res Hospital Ligando induzìvel para a integrina alfa 1 beta 1 e empregos
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US20080187508A1 (en) * 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
AU2006315428B2 (en) * 2005-11-16 2011-12-01 The University Of Tennessee Research Foundation Methods of treating fibrosing diseases by induction of immune tolerance
PL2200622T5 (pl) 2007-09-19 2016-08-31 Pluristem Ltd Adherentne komórki z tkanki tłuszczowej i łożyska i ich zastosowanie w terapii
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
CN114887034B (zh) * 2022-07-14 2022-10-28 中山莱博瑞辰生物医药有限公司 LLP2A-Ale在制备用于治疗和/或预防外周血淋巴细胞减少症的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
CA2329757C (en) * 1998-05-22 2013-11-19 Boys Town National Research Hospital Use of .alpha.1.beta.1 integrin receptor inhibitors and tgf-.beta.1 inhibitors in the treatment of kidney disease
NZ515686A (en) * 1999-06-01 2005-01-28 Biogen Inc A blocking monoclonal antibody to integrin VLA-1 and its use for the treatment of inflammatory disorders such as arthritis
GB2356401A (en) * 1999-11-19 2001-05-23 Proteom Ltd Method for manipulating protein or DNA sequence data
BR0315054A (pt) * 2002-11-01 2005-08-16 Boys Town Nat Res Hospital Ligando induzìvel para a integrina alfa 1 beta 1 e empregos

Also Published As

Publication number Publication date
AU2003287435A2 (en) 2004-06-07
NO20052495D0 (no) 2005-05-24
EP1562632A2 (en) 2005-08-17
KR20050084921A (ko) 2005-08-29
US20040253241A1 (en) 2004-12-16
EP1562632A4 (en) 2007-01-17
PL376714A1 (pl) 2006-01-09
JP2006516024A (ja) 2006-06-15
AU2003287435A1 (en) 2004-06-07
NO20052495L (no) 2005-07-25
CA2504125A1 (en) 2004-05-21
CN1826137A (zh) 2006-08-30
EP1562632B1 (en) 2012-12-05
US7348002B2 (en) 2008-03-25
WO2004041846A3 (en) 2005-04-28
US20080227121A1 (en) 2008-09-18
MXPA05004563A (es) 2005-07-26
WO2004041846A2 (en) 2004-05-21
US7662382B2 (en) 2010-02-16
IS7832A (is) 2005-04-29
EA200500576A1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
TR200100146T2 (tr) Antidepresan etkiye sahip madde
BR0316670A (pt) Anticorpos quiméricos e humanizados para integrina (alfa)5ß1 que modulam a angiogênese
ES2103936T3 (es) Cepillo de dientes con una zona de union flexible en la cabeza.
UY26850A1 (es) Activadores de la benzeno acetamida glucoquinasa alfa-acil y alfa-heteroátomo sustituida.
DE60230450D1 (de) Druckempfindliche klebefasern mit verstärkungsmaterial
ATE334564T1 (de) Kommunikationssystem
BR0315054A (pt) Ligando induzìvel para a integrina alfa 1 beta 1 e empregos
BR0304213A (pt) Processo para a sìntese industrial de ranelato de estrÈncio e os seus hidratos
BR9907218A (pt) Anticorpo monoclonal anti alfav-integrina e seu uso para inibir a fixação de alfav-beta6-integrina à fibronectina
HN2004000079S1 (es) Diseno de botella
BRPI0402583A (pt) Mangueira para refrigerante
ATE392649T1 (de) Verschlussteil und damit versehener tonerbehälter
BR0314716A (pt) Anticorpos de subunidade alfa de lfa-1 e métodos de uso
BR0316400A (pt) agentes branqueadores fluorescentes anfotéricos
BR0316810A (pt) Uso de um agonista de ppar(alfa) e metformina para diminuir os triglicerìdeos séricos
BRPI0502037A (pt) Processo para a sìntese de (7-metóxi-1-naftil)acetonitrila e sua aplicação na sìntese de agomelatina
BR0006269A (pt) Aplicação de dialquilpolissulfetos para o amassamento de borrachas naturais e de sìntese
BRPI0410574A (pt) etiqueta de fios de poliéster e instalação para sua fabricação
ATE443135T1 (de) Fluoreszenzprotein und pigmentprotein
BR0202016B1 (pt) processo para moagem de pó de alfa alumina.
BR9914076A (pt) Materiais de fixação elásticos para produtos de cuidado pessoal
BRPI0413718A (pt) ativadores de plasminogênio tendo uma capacidade reduzida de ligar lisina
BR0303500A (pt) Anticorpo monoclonal especìfico para um epìtope de glicoproteìna codificada pelo vìrus da imunodeficiência felina inativo
BR8000262U (pt) Dispositivo retratil para carregar crachas, chaves, cartoes-magneticos e afins.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A., 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.